SUNSHINE BIOPHARMA ANNOUNCES PUBLICATION OF SIGNIFICANT CORONAVIRUS RESEARCH RESULTS IN THE JOURNAL OF MEDICINAL CHEMISTRY
SUNSHINE BIOPHARMA HAS LAUNCHED NINE NEW GENERIC PRESCRIPTION DRUGS IN 2024: NOW MARKETING SIXTY-ONE GENERIC DRUGS IN CANADA
SUNSHINE BIOPHARMA REPORTS 2024 SECOND QUARTER RESULTS: SECOND QTR REVENUES UP 67%, YTD REVENUES UP 61%
SUNSHINE BIOPHARMA’S NORA PHARMA RECEIVES HEALTH CANADA APPROVAL FOR NIOPEG®, A BIOSIMILAR OF NEULASTA®